ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

419
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
Refresh
10 Nov 2020 19:22

Shenzhou International Placement - Conditioned for Selldowns

Ma Jianrong, founder of Shenzhou and senior managers are looking to sell 37.5m shares worth approximately, US$659m. Post share sale, the entities...

Share
bullishWuxi Biologics
01 Sep 2020 18:25

Wuxi Biologics Placement - Another One Before Lock-Up, but Just in Time for the Index Inclusion

Wuxi Biologics (Cayman) Inc (2269 HK) has seen a total of ten placements since listing in Jun 2017. We've covered all of the deals. Given that the...

Logo
414 Views
Share
23 Aug 2020 15:21

Hong Kong Connect Weekly: Meituan, Smoore, SMIC, Wuxi Biologics

In our weekly HK Connect Flow series, we aim to highlight key stocks and sectors which the mainland investors traded via the southbound Hong Kong...

Logo
227 Views
Share
bullishMeituan
17 Aug 2020 12:37

Hang Seng Index - Possible Changes in Upcoming Reviews

The Hang Seng Indexes Company Limited (HSIL) announced the results of its September review of the Hang Seng Family of Indexes post market close on...

Logo
425 Views
Share
bullishWuxi Biologics
15 Aug 2020 10:42

Hang Seng Index Rebalance - Big Turnover, Big Impact, Some Surprises and More Changes to Come

The Hang Seng Indexes Company Limited (HSIL) announced the results of its review of the Hang Seng Family of Indexes post market close on 14 August....

Logo
967 Views
Share
x